Join the club for FREE to access the whole archive and other member benefits.

An effective immunotherapy for advanced prostate cancer

Only 5% saw their tumours shrink, but may be more successful if used earlier

28-Nov-2019

Key points from article :

Immunotherapy can be effective in some men with advanced prostate cancer.

The drug pembrolizumab caused the tumour to shrink or disappear in 1 in 20 with advanced disease.

Although this 5 % means a small number, some of them gained years of extra life.

Another 19% saw evidence of some sort of improvement.

This trial involved 258 men with advanced prostate cancer who didn't respond to other treatment options.

Those who have mutations in genes involved in repairing DNA in the tumour may benefit more.

Research by the Institute of Cancer Research and the Royal Marsden, published in Journal of Clinical Oncology.

Mentioned in this article:

Click on resource name for more details.

Johann de Bono

Consultant at the Institute of Cancer Research

Journal of Clinical Oncology

Scientific journal of American Society of Clinical Oncology is published 3 times per month

Paul Workman

Chief Executive and President of The Institute of Cancer Research.

Royal Marsden NHS Foundation Trust

Hospital dedicated to cancer diagnosis, treatment, research and education.

The Institute of Cancer Research (ICR)

One of the world’s most influential cancer research organizations

Topics mentioned on this page:
Cancer